Don’t miss the latest developments in business and finance.

Lupin gets approval to market Bimatroprost Ophthalmic Solution, 0.03%

Image
Capital Market
Last Updated : Feb 23 2015 | 3:15 PM IST

From USFDA

Lupin announced that it has received final approval for its Bimatroprost Ophthalmic Solution, 0.03% from the United States Food & Drug Administration (FDA) to market a generic version of Allergen Inc.'s Lumigan Ophthalmic Solution 0.03%.

Powered by Capital Market - Live News

More From This Section

First Published: Feb 23 2015 | 1:50 PM IST

Next Story